
Alcon Inc.
ALCNYSEHealthcareMedical - Specialties
Previous close
$73.63
+$0.70 · +0.96%
ALC company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
74
Undervalued
Momentum
39
Weakening
Sentiment
62
Bullish
Risk resilience
68
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAlcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
- Industry
- Medical - Specialties
- Sector
- Healthcare
- Headquarters
- CH
- CEO
- David J. Endicott
- Listed since
- Apr 9, 2019
- Employees
- 25,000
Market position
Day range
Current $73.63
52-week range
Current $73.63
- Open
- $72.80
- Previous close
- $72.93
- Volume
- 994.18K
- 0.47× average
- Average volume
- 2.13M
- Average daily volume
- Market cap
- 35.91B USD
- Beta
- 0.69
- Market reference 1
- 50-day average
- $69.1474
- +6.48% above average
- 200-day average
- $74.6501
- -1.37% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 42.73B USD
- EV / EBITDA
- 18.17×
- Earnings yield
- 2.51%
- Free cash flow yield
- 4.12%
Profitability & efficiency
- Return on equity
- 4.45%
- Return on assets
- 3.11%
- Return on invested capital
- 3.94%
Financial health
- Current ratio
- 2.12×
- Altman Z-score
- 2.85
- Piotroski F-score
- 8 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10.4B USD | 9.91B USD | 9.46B USD | 8.72B USD | 8.29B USD |
| Cost of goods sold | 4.66B USD | 4.4B USD | 4.21B USD | 3.97B USD | 3.64B USD |
| Gross profit | 5.75B USD | 5.51B USD | 5.25B USD | 4.75B USD | 4.65B USD |
| Research and development | 990M USD | 876M USD | 859M USD | 702M USD | 842M USD |
| Selling, general, and administrative | 3.45B USD | 3.25B USD | 3.21B USD | 3.07B USD | 3.08B USD |
| Operating expenses | 4.39B USD | 4.1B USD | 4.21B USD | 4.08B USD | 4.07B USD |
| Interest income | 74M USD | 81.45M USD | 34M USD | 16.52M USD | 3.01M USD |
| Interest expense | 204M USD | 186.18M USD | 189M USD | 138.4M USD | 120.26M USD |
| Depreciation and amortization | 1.19B USD | 1.23B USD | 1.22B USD | 1.16B USD | 1.22B USD |
| Operating income | 1.36B USD | 1.41B USD | 1.04B USD | 672M USD | 580M USD |
| Net income | 980M USD | 1.02B USD | 974M USD | 335M USD | 376M USD |
Company facts updated Aug 24, 2026.
ALC peers
ETFs holding ALC
Funds reporting this stock among their holdings, ordered by reported position size.
Kovitz Core Equity ETFEQTY39.45M3.06%1.28B USD0.99%$29.875+0.83%
Dimensional - International Value ETFDFIV35.6M0.16%22.06B USD0.27%$58.31+0.88%
Dimensional - International Core Equity Market ETFDFAI19.13M0.11%18.23B USD0.18%$43.35+0.81%
Dimensional - International Core Equity 2 ETFDFIC16.13M0.11%15.43B USD0.22%$39.405+0.83%
Dimensional World ex U.S. Core Equity 2 ETFDFAX8.52M0.07%12.57B USD0.28%$38.16+0.82%
Running Oak Efficient Growth ETFRUNN7.67M1.86%392.04M USD0.58%$35.2948+0.53%
John Hancock Investments - Multifactor Developed International ETFJHMD3.06M0.32%971.55M USD0.39%$46.405+0.66%
Invesco RAFI Developed Markets ex-U.S. ETFPXF2.89M0.10%3B USD0.43%$79.77+0.90%
Kovitz Core Equity ETFEQTY- Market value
- 39.45M
- Weight
- 3.06%
- AUM
- 1.28B USD
- Expense ratio
- 0.99%
- Price / 1D
- $29.875+0.83%
Dimensional - International Value ETFDFIV- Market value
- 35.6M
- Weight
- 0.16%
- AUM
- 22.06B USD
- Expense ratio
- 0.27%
- Price / 1D
- $58.31+0.88%
Dimensional - International Core Equity Market ETFDFAI- Market value
- 19.13M
- Weight
- 0.11%
- AUM
- 18.23B USD
- Expense ratio
- 0.18%
- Price / 1D
- $43.35+0.81%
Dimensional - International Core Equity 2 ETFDFIC- Market value
- 16.13M
- Weight
- 0.11%
- AUM
- 15.43B USD
- Expense ratio
- 0.22%
- Price / 1D
- $39.405+0.83%
Dimensional World ex U.S. Core Equity 2 ETFDFAX- Market value
- 8.52M
- Weight
- 0.07%
- AUM
- 12.57B USD
- Expense ratio
- 0.28%
- Price / 1D
- $38.16+0.82%
Running Oak Efficient Growth ETFRUNN- Market value
- 7.67M
- Weight
- 1.86%
- AUM
- 392.04M USD
- Expense ratio
- 0.58%
- Price / 1D
- $35.2948+0.53%
John Hancock Investments - Multifactor Developed International ETFJHMD- Market value
- 3.06M
- Weight
- 0.32%
- AUM
- 971.55M USD
- Expense ratio
- 0.39%
- Price / 1D
- $46.405+0.66%
Invesco RAFI Developed Markets ex-U.S. ETFPXF- Market value
- 2.89M
- Weight
- 0.10%
- AUM
- 3B USD
- Expense ratio
- 0.43%
- Price / 1D
- $79.77+0.90%
Continue in GoAI
Research ALCresearch.disclaimer





